Priming With Rhinovirus Protects Mice Against a Lethal Pulmonary Coronavirus InfectionArticle Published on 2022-05-302023-07-09 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] coronaviral infection coronavirus interferon mouse hepatitis virus mouse model respiratory virus co-infection rhinovirus [DOI] 10.3389/fimmu.2022.886611 PMC 바로가기
Parsing the role of NSP1 in SARS-CoV-2 infectionArticle Published on 2022-05-262023-06-16 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, [키워드] Coronaviruses Host shutoff interferon nsp1 RNA SARS-CoV-2 Translation regulation [DOI] 10.1016/j.celrep.2022.110954 PMC 바로가기 [Article Type] Article
Novel Pegylated Interferon for the Treatment of Chronic Viral HepatitisReview Published on 2022-05-252023-06-13 Journal: Viruses [Category] B형 간염, [키워드] Chronic Hepatitis B chronic hepatitis C Chronic hepatitis D clinical trial interferon Ropeginterferon Alfa-2b [DOI] 10.3390/v14061128 PMC 바로가기 [Article Type] Review
Distinct Immunological Profiles Help in the Maintenance of Salivary Secretory IgA Production in Mild Symptoms COVID-19 PatientsOriginal Research Published on 2022-05-242023-06-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, [키워드] Cytokines interferon interleukin mucosal immunity Saliva SARS-CoV-2 [DOI] 10.3389/fimmu.2022.890887 PMC 바로가기 [Article Type] Original Research
Severe Acute Respiratory Syndrome Coronavirus 2 ORF8 Protein Inhibits Type I Interferon Production by Targeting HSP90B1 Signaling중증 급성 호흡기 증후군 코로나바이러스 2 ORF8 단백질은 HSP90B1 신호 전달을 표적으로 하여 I형 인터페론 생산을 억제합니다Article Published on 2022-05-232022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Amino acid Antiviral caused coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 exhibit explanation function Genotype genotypes global pandemic high mutation rate high mutation rates HSP90B1 IFN-I IFN-β immune evasion Immune suppression implication individual induce inhibit inhibitory effect interact interferon interferon response investigated IRF3 ISG15 leucine MDA5 mechanism Mutation no difference nuclear translocation ORF8 ORF8 protein pandemic pathogenic pathway poly(I:C) Production Protein provide reported respiratory RIG-I SARS-CoV-2 Serine severe acute respiratory syndrome Coronavirus signaling pathway strain suppress targeting the SARS-CoV-2 Treatment Type type I interferon variant [DOI] 10.3389/fcimb.2022.899546 PMC 바로가기 [Article Type] Article
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusPharmacometrics Published on 2022-05-212024-09-04 Journal: Journal of clinical pharmacology [Category] 대상포진, [키워드] anifrolumab interferon Pharmacodynamics pharmacokinetics systemic lupus erythematosus (SLE) [DOI] 10.1002/jcph.2054 PMC 바로가기 [Article Type] Pharmacometrics
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses코로나19 입원 환자를 위한 렘데시비르 및 기타 3가지 약물: WHO 연대 무작위 시험의 최종 결과 및 업데이트된 메타 분석Meta-Analysis Published on 2022-05-212022-09-11 Journal: Lancet (London, England) [Category] 신약개발, 임상, 치료제, [키워드] 1:1 allocation Analysis antiviral drugs assigned average both groups Characteristics Compliance controls country COVID-19 COVID-19 diagnosis database death died discharge discharged disease severity drug drugs eligible patient Endpoint enrolled exclusion Final futility hospital Hospital mortality hospitalised hospitalised patient Hospitalised patients Hydroxychloroquine in both groups in-hospital mortality Inpatient Inpatients interferon ISRCTN Kaplan-Meier Local Lopinavir meta-analyses Meta-analysis Mortality mortality analysis mortality rate ratio no significant effect occurred Open-label outcome oxygen participant Patient patients patients with COVID-19 Placebo placebos primary endpoint progressed progression proportion randomisation Randomised trial Randomly rate ratio receive recruited regions Registered Remdesivir reported secondary Secondary endpoints solidarity Solidarity trial Standard of care study drug the WHO treatment period Trial Ventilated Ventilation were given WHO [DOI] 10.1016/S0140-6736(22)00519-0 PMC 바로가기 [Article Type] Meta-Analysis
SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodiesSARS-CoV-2 숙주 차단은 타고난 NK 세포 기능에 영향을 미치지만 항체 의존적 NK 활성은 스파이크가 아닌 항체를 통해 강력하게 활성화됩니다Article Published on 2022-05-192022-09-11 Journal: eLife [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료법, [키워드] a minor activated activating Activation ADCC ADNKA Analysis antibody Cell cellular immunity correlated cytokine dependent on Depletion Disease progression dominant downregulation Effect Efficacy epithelial cells evade expression functions genetic risk factors identify immune response Immunity immunology Impact implication infected cell Infection Infectious disease Inflammation Innate immunity interferon interferon response Ligand Lung epithelial cells mechanism membrane MHC-I MICA Microbiology minor Most patients natural infection Nectin1 neutralisation NK cell NK cells nsp1 nsp14 nucleocapsid occurred ORF3a outcome overcome Pathogenesis patients pro-inflammatory cytokine protein synthesis Proteins proteomic reduction in response SARS-CoV-2 SARS-CoV2 second dose specific antibodies spike-specific antibodies Spike-specific antibody surface protein sustained the disease ULBP2 understanding vaccination Vaccine Vaccine design vaccine efficacy Vaccine-induced immunity virus viruses [DOI] 10.7554/eLife.74489 PMC 바로가기 [Article Type] Article
Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 PatientsArticle Published on 2022-05-192023-07-09 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] cellular immunity COVID-19 interferon SARS-CoV-2 Th1 cytokines [DOI] 10.3389/fimmu.2022.911859 PMC 바로가기
Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a TreatmentArticle Published on 2022-05-192023-06-13 Journal: Frontiers in Immunology [Category] B형 간염, Fulltext, [키워드] Chronic Hepatitis B functional cure hepatitis B surface antigen interferon plasmacytoid dendritic cells [DOI] 10.3389/fimmu.2022.891424 PMC 바로가기